Global Cannabinoid Based Drug Discovery And Development Market

Cannabinoid-based drug discovery and development refer to the scientific process of identifying, designing, and bringing to market medicines that act on the body’s endocannabinoid system (ECS) using compounds derived from Cannabis sativa (like THC and CBD), their synthetic analogs, or newly engineered molecules that target cannabinoid receptors (CB1, CB2) and related pathways. These efforts span basic research, medicinal chemistry, preclinical testing, and clinical trials, with the goal of proving safety and efficacy for therapeutic use in regulated medical settings. Cannabinoids have shown promise for a range of conditions including chronic pain, epilepsy, neurodegenerative disorders, inflammatory diseases, psychiatric conditions, and nausea or appetite loss by modulating pain, inflammation, mood, and neurological signaling. For example, in March 2024, Brains Bioceutical Corp. announced breakthroughs in pharmaceutical-grade cannabinoid active ingredients, including solid THC and certified Cannabinol (CBN) APIs, which support clinical research and future therapeutic products.